Martinsried, 12 September 2022 - The flagship project "DigiMed Bayern - for the medicine of the future" is being extended by one year. Bavaria's Minister of Health, Klaus Holetschek, personally handed over the extension notice to the managing BioM Biotech Cluster Development GmbH last Friday in the presence of top-class DigiMed Bayern partners from science and hospitals. DigiMed Bayern aims to prevent heart attacks and strokes and stands for data-based personalised medicine - using the widespread disease of atherosclerosis as an example. [...]
Please find the complete press release here.
The flagship P4-medicine project DigiMed Bayern was launched at the end of 2018 with more than € 20 million funding by the Bavarian State Ministry of Health and Care. DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.
Planned duration of the project:
Q4 2018 bis Q4 2023
project extension 30.11.2024
Deutsches Herzzentrum München
BioM Biotech Cluster Development GmbH